Characterization of methadone as a β-arrestin-biased μ-opioid receptor agonist

Seira Doi1, Tomohisa Mori1, Naoki Uzawa1

  • 1Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Ebara, Shinagawa-ku, Tokyo, Japan.

Molecular Pain
|June 19, 2016
PubMed
Abstract

Insights

Methadone acts as a biased agonist at the µ-opioid receptor, similar to fentanyl, rather than primarily through NMDA receptor blockade. This explains its unique pharmacological effects compared to morphine.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Receptor Biology

Background:

  • Methadone is a µ-opioid receptor agonist with a controversial mechanism of action.
  • Previous research suggested methadone's effects are mediated by NMDA receptor blockade.
  • The distinct pharmacological profile of methadone compared to other opioids remains unclear.

Purpose of the Study:

  • To investigate the pharmacological profile of methadone.
  • To compare methadone with fentanyl and morphine regarding NMDA receptor binding and µ-opioid receptor activity.
  • To elucidate the mechanism behind methadone's unique effects.

Main Methods:

  • Discriminative stimulus effect studies in rats.
  • In vitro assays for NMDA receptor binding.
  • Analysis of µ-opioid receptor internalization and β-arrestin recruitment.

Main Results:

  • Fentanyl substituted for methadone's effects; high-dose morphine showed limited substitution.
  • MK-801, an NMDA receptor antagonist, did not substitute for methadone's effects.
  • Methadone and fentanyl induced µ-opioid receptor internalization and β-arrestin-2 recruitment, unlike morphine.

Conclusions:

  • Methadone acts as a β-arrestin-biased µ-opioid receptor agonist, similar to fentanyl.
  • NMDA receptor blockade is not the primary mechanism for methadone's pharmacological effects.
  • These findings clarify the unique action of methadone among opioid agonists.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
6.1K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.4K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.8K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.5K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.1K
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.4K